What is QHSLab Inc's earnings per share (EPS)?

QHSLab Inc (USAQ) reported diluted earnings per share of $0.02 for fiscal year 2025. This represents a 166.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

QHSLab Inc Financials

USAQ

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows QHSLab Inc (USAQ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI USAQ FY2025 2026-05-14

Gross-margin expansion and a balance-sheet reset transformed a previously cash-tight business into one with workable liquidity.

Net income turned positive even though operating margin narrowed from 9.7% to 4.9%, so the turnaround did not come from stronger core profitability alone. At the same time, liabilities fell from $2.4M to $546K, which helps explain why the bottom line improved faster than the operating line.

Gross margin climbed from 56.3% to 67.3% over two years, showing the economics before overhead improved materially. But operating margin was only 4.9% because R&D reached $485K, so much of that gain is still being reinvested rather than retained.

Liquidity now looks serviceable: cash finished at $636K and the current ratio moved back above 1.0x after prior years below that line. But shares outstanding rose from 10.8M to 15.0M, so part of the stronger cash position appears to have been financed externally rather than generated by the business itself.

Financial Health Signals

Financial Profile 55/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of QHSLab Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

QHSLab Inc has an operating margin of 4.9%, meaning the company retains $5 of operating profit per $100 of revenue. This below-average margin results in a low score of 27/100, suggesting thin profitability after operating expenses. This is down from 9.7% the prior year.

Growth

QHSLab Inc's revenue surged 26.3% year-over-year to $2.7M, reflecting rapid business expansion. This strong growth earns a score of 97/100.

Leverage

100

QHSLab Inc carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

QHSLab Inc's current ratio of 1.96 indicates adequate short-term liquidity, earning a score of 35/100. The company can meet its near-term obligations, though with limited headroom.

Returns

QHSLab Inc earns a strong 28.1% return on equity (ROE), meaning it generates $28 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 74/100.

Altman Z-Score Safe

7.75

QHSLab Inc scores 7.75, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($7.8M) relative to total liabilities ($546K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

5/9

QHSLab Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

-0.39x

For every $1 of reported earnings, QHSLab Inc generates $-0.39 in operating cash flow (-$178K OCF vs $457K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

0.6x

QHSLab Inc earns $0.6 in operating income for every $1 of interest expense ($131K vs $237K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.7M

YoY+26.3%

5Y CAGR+84.9%

QHSLab Inc generated $2.7M in revenue in fiscal year 2025. This represents an increase of 26.3% from the prior year.

EBITDA

$222K

YoY-37.0%

QHSLab Inc's EBITDA was $222K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 37.0% from the prior year.

Net Income

$457K

YoY+276.4%

QHSLab Inc reported $457K in net income in fiscal year 2025. This represents an increase of 276.4% from the prior year.

EPS (Diluted)

$0.02

YoY+166.7%

QHSLab Inc earned $0.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 166.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$636K

YoY+304.8%

5Y CAGR+46.5%

QHSLab Inc held $636K in cash against $91K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

15M

YoY+39.1%

5Y CAGR+18.0%

10Y CAGR+9.6%

QHSLab Inc had 15M shares outstanding in fiscal year 2025. This represents an increase of 39.1% from the prior year.

Margins & Returns

Gross Margin

67.3%

YoY+3.6pp

5Y CAGR+27.0pp

QHSLab Inc's gross margin was 67.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.6 percentage points from the prior year.

Operating Margin

4.9%

YoY-4.8pp

5Y CAGR+225.8pp

QHSLab Inc's operating margin was 4.9% in fiscal year 2025, reflecting core business profitability. This is down 4.8 percentage points from the prior year.

Net Margin

17.0%

YoY+29.1pp

5Y CAGR+279.9pp

QHSLab Inc's net profit margin was 17.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 29.1 percentage points from the prior year.

Return on Equity

28.1%

QHSLab Inc's ROE was 28.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$485K

YoY+64.7%

5Y CAGR+37.6%

QHSLab Inc invested $485K in research and development in fiscal year 2025. This represents an increase of 64.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

USAQ Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.7M+26.3%	$2.1M+51.3%	$1.4M+13.3%	$1.2M-12.1%	$1.4M+1035.8%	$125K
Cost of Revenue	$881K+13.8%	$774K+25.8%	$615K-1.3%	$624K-16.1%	$744K+899.0%	$74K
Gross Profit	$1.8M+33.4%	$1.4M+71.1%	$794K+28.1%	$620K-7.6%	$671K+1239.0%	$50K
R&D Expenses	$485K+64.7%	$294K+37.6%	$214K+12.6%	$190K+109.2%	$91K-7.5%	$98K
SG&A Expenses	$439K+58.8%	$276K+6.7%	$259K-33.1%	$388K-14.6%	$454K+244.6%	$132K
Operating Income	$131K-36.2%	$206K+185.7%	-$240K+57.2%	-$561K-11.6%	-$502K-82.6%	-$275K
Interest Expense	$237K-48.9%	$465K+101.8%	$230K-46.8%	$433K+75.8%	$246K+695.5%	$31K
Income Tax	N/A	N/A	N/A	$0	N/A	N/A
Net Income	$457K+276.4%	-$259K+44.6%	-$468K+53.0%	-$996K-29.3%	-$770K-135.2%	-$327K
EPS (Diluted)	$0.02+166.7%	$-0.03+40.0%	$-0.05+54.5%	$-0.11	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$729K+3.5%	$704K-4.5%	$737K+21.7%	$605K-6.2%	$645K+3.1%	$626K+15.0%	$544K+15.1%	$473K
Cost of Revenue	$258K+19.6%	$216K-11.5%	$243K+17.9%	$206K-4.2%	$215K+0.8%	$214K+19.4%	$179K+0.3%	$179K
Gross Profit	$471K-3.6%	$488K-1.1%	$494K+23.7%	$399K-7.2%	$430K+4.3%	$412K+12.9%	$365K+24.0%	$294K
R&D Expenses	$121K+4.5%	$116K-12.9%	$133K+18.2%	$112K-9.4%	$124K+15.3%	$108K+35.3%	$80K+22.7%	$65K
SG&A Expenses	$208K+71.8%	$121K+88.9%	$64K-35.1%	$99K-36.6%	$156K+86.5%	$83K+49.7%	$56K+17.4%	$47K
Operating Income	-$94K-365.8%	$36K-63.1%	$96K+735.1%	$12K+195.7%	-$12K-116.5%	$73K-18.0%	$89K+197.3%	$30K
Interest Expense	$10K-77.6%	$43K-32.3%	$63K-2.5%	$64K-4.6%	$68K-81.3%	$361K+817.3%	$39K+19.7%	$33K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$104K-118.7%	$557K+1565.8%	$33K+163.1%	-$53K+33.5%	-$80K+72.3%	-$288K-677.9%	$50K+1822.0%	-$3K
EPS (Diluted)	$0.00	N/A	$0.00	$0.00+100.0%	$-0.01	N/A	$0.00	$0.00

USAQ Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.2M+20.6%	$1.8M+7.0%	$1.7M-14.1%	$2.0M-11.4%	$2.2M+641.4%	$298K
Current Assets	$883K+109.8%	$421K+169.5%	$156K-45.3%	$286K-35.9%	$446K+67.5%	$266K
Cash & Equivalents	$636K+304.8%	$157K+204.7%	$52K-71.1%	$179K-37.7%	$287K+204.1%	$94K
Inventory	$36K-14.3%	$42K+65.9%	$25K-51.4%	$52K-21.1%	$66K-34.1%	$100K
Accounts Receivable	$191K-2.8%	$196K+174.7%	$71K+49.5%	$48K-32.3%	$70K+16.4%	$61K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$546K-77.3%	$2.4M+17.0%	$2.1M+9.3%	$1.9M+35.9%	$1.4M+52.8%	$906K
Current Liabilities	$450K-81.3%	$2.4M+17.0%	$2.1M+20.5%	$1.7M+95.1%	$875K+307.7%	$215K
Long-Term Debt	$91K	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.6M+367.4%	-$608K-61.8%	-$376K-592.6%	$76K-90.7%	$824K+235.5%	-$608K
Retained Earnings	-$3.9M+9.9%	-$4.3M-8.7%	-$4.0M-13.3%	-$3.5M-39.5%	-$2.5M-44.0%	-$1.7M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$1.9M-13.0%	$2.2M+25.2%	$1.7M+1.4%	$1.7M+2.5%	$1.7M-7.3%	$1.8M+2.0%	$1.8M+3.9%	$1.7M
Current Assets	$619K-29.9%	$883K+106.0%	$429K+11.0%	$386K+18.5%	$326K-22.6%	$421K+20.5%	$349K+41.9%	$246K
Cash & Equivalents	$362K-43.1%	$636K+301.6%	$158K-5.9%	$168K+175.7%	$61K-61.1%	$157K+63.8%	$96K-7.9%	$104K
Inventory	$28K-23.1%	$36K+34.5%	$27K-37.0%	$42K+44.8%	$29K-30.1%	$42K+4.4%	$40K+543.9%	$6K
Accounts Receivable	$201K+5.6%	$191K-9.3%	$210K+41.8%	$148K-24.0%	$195K-0.6%	$196K-1.1%	$198K+50.7%	$132K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$368K-32.6%	$546K-76.7%	$2.3M-0.4%	$2.4M+4.2%	$2.3M-6.1%	$2.4M+14.6%	$2.1M+0.8%	$2.1M
Current Liabilities	$368K-18.2%	$450K-80.8%	$2.3M-0.4%	$2.4M+4.2%	$2.3M-6.1%	$2.4M+15.2%	$2.1M+0.3%	$2.1M
Long-Term Debt	$37K-59.3%	$91K	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.5M-6.4%	$1.6M+366.0%	-$611K+5.2%	-$644K-9.0%	-$591K+2.7%	-$608K-81.3%	-$335K+12.9%	-$385K
Retained Earnings	-$4.0M-2.7%	-$3.9M+11.9%	-$4.4M+0.7%	-$4.5M-1.2%	-$4.4M-1.8%	-$4.3M-7.9%	-$4.0M+1.2%	-$4.1M

USAQ Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$178K-225.1%	$142K+189.2%	-$160K+54.5%	-$351K+1.1%	-$355K-114.3%	-$166K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$37K+76.0%	-$155K-387.6%	-$32K
Financing Cash Flow	$301K+916.5%	-$37K-213.3%	$33K-88.4%	$280K-60.1%	$702K+161.9%	$268K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$200K+22.4%	-$258K-10027.1%	$3K-98.0%	$127K+356.4%	-$50K-190.0%	$55K+197.3%	-$57K-164.7%	$87K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$74K-119.4%	$380K+3121.4%	-$13K+36.3%	-$20K+57.6%	-$47K-854.2%	$6K-87.2%	$48K+196.4%	-$50K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

USAQ Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	67.3%+3.6pp	63.7%+7.4pp	56.3%+6.5pp	49.8%+2.4pp	47.4%+7.2pp	40.2%
Operating Margin	4.9%-4.8pp	9.7%+26.7pp	-17.0%+28.1pp	-45.1%-9.6pp	-35.5%+185.4pp	-220.9%
Net Margin	17.0%+29.1pp	-12.2%+21.1pp	-33.2%+46.9pp	-80.1%-25.7pp	-54.4%+208.4pp	-262.9%
Return on Equity	28.1%	N/A	N/A	-1306.3%-1212.9pp	-93.5%	N/A
Return on Assets	21.1%+35.5pp	-14.4%+13.4pp	-27.9%+23.0pp	-50.9%-16.0pp	-34.9%+75.0pp	-109.9%
Current Ratio	1.96+1.8	0.17+0.1	0.08-0.1	0.17-0.3	0.51-0.7	1.24
Debt-to-Equity	0.06+4.0	-3.96+1.5	-5.48-30.1	24.67+23.0	1.68+3.2	-1.49
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	64.6%-4.8pp	69.4%+2.4pp	67.0%+1.1pp	65.9%-0.7pp	66.6%+0.8pp	65.8%-1.2pp	67.1%+4.8pp	62.2%
Operating Margin	-13.0%-18.0pp	5.0%-8.0pp	13.1%+11.2pp	1.9%+3.8pp	-1.9%-13.5pp	11.7%-4.7pp	16.4%+10.0pp	6.3%
Net Margin	-14.3%-93.3pp	79.1%+74.5pp	4.5%+13.3pp	-8.8%+3.6pp	-12.3%+33.6pp	-45.9%-55.1pp	9.1%+9.7pp	-0.6%
Return on Equity	-6.8%-41.1pp	34.3%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-5.5%-31.1pp	25.6%+23.7pp	1.9%+5.0pp	-3.1%+1.7pp	-4.8%+11.2pp	-16.0%-18.8pp	2.8%+3.0pp	-0.2%
Current Ratio	1.68-0.3	1.96+1.8	0.18+0.0	0.16+0.0	0.14-0.0	0.170.0	0.17+0.0	0.12
Debt-to-Equity	0.02-0.0	0.06+3.9	-3.84-0.2	-3.65+0.2	-3.82+0.1	-3.96+2.3	-6.26-0.9	-5.41
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Ir-Med Inc IRME

$769K

Therma Bright Inc TBRIF

$2.1M

Bionoid Pharma Inc BINP

$1.6M

Cyduct Diagnostics Inc CYDX

$3.3M

Kelyniam Global Inc KLYG

$5.5M

Frequently Asked Questions

What is QHSLab Inc's annual revenue?

QHSLab Inc (USAQ) reported $2.7M in total revenue for fiscal year 2025. This represents a 26.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is QHSLab Inc's revenue growing?

QHSLab Inc (USAQ) revenue grew by 26.3% year-over-year, from $2.1M to $2.7M in fiscal year 2025.

Is QHSLab Inc profitable?

Yes, QHSLab Inc (USAQ) reported a net income of $457K in fiscal year 2025, with a net profit margin of 17.0%.

What is QHSLab Inc's EBITDA?

QHSLab Inc (USAQ) had EBITDA of $222K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does QHSLab Inc have?

As of fiscal year 2025, QHSLab Inc (USAQ) had $636K in cash and equivalents against $91K in long-term debt.

What is QHSLab Inc's gross margin?

QHSLab Inc (USAQ) had a gross margin of 67.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is QHSLab Inc's operating margin?

QHSLab Inc (USAQ) had an operating margin of 4.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is QHSLab Inc's net profit margin?

QHSLab Inc (USAQ) had a net profit margin of 17.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is QHSLab Inc's return on equity (ROE)?

QHSLab Inc (USAQ) has a return on equity of 28.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is QHSLab Inc's operating cash flow?

QHSLab Inc (USAQ) generated -$178K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are QHSLab Inc's total assets?

QHSLab Inc (USAQ) had $2.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does QHSLab Inc spend on research and development?

QHSLab Inc (USAQ) invested $485K in research and development during fiscal year 2025.

How many shares does QHSLab Inc have outstanding?

QHSLab Inc (USAQ) had 15M shares outstanding as of fiscal year 2025.

What is QHSLab Inc's current ratio?

QHSLab Inc (USAQ) had a current ratio of 1.96 as of fiscal year 2025, which is generally considered healthy.

What is QHSLab Inc's debt-to-equity ratio?

QHSLab Inc (USAQ) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is QHSLab Inc's return on assets (ROA)?

QHSLab Inc (USAQ) had a return on assets of 21.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is QHSLab Inc's cash runway?

Based on fiscal year 2025 data, QHSLab Inc (USAQ) had $636K in cash against an annual operating cash burn of $178K. This gives an estimated cash runway of approximately 43 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is QHSLab Inc's Altman Z-Score?

QHSLab Inc (USAQ) has an Altman Z-Score of 7.75, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is QHSLab Inc's Piotroski F-Score?

QHSLab Inc (USAQ) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are QHSLab Inc's earnings high quality?

QHSLab Inc (USAQ) has an earnings quality ratio of -0.39x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can QHSLab Inc cover its interest payments?

QHSLab Inc (USAQ) has an interest coverage ratio of 0.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is QHSLab Inc?

QHSLab Inc (USAQ) scores 55 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.